Stoke Therapeutics settles shareholder derivative lawsuit; $590K in fees, governance reforms

Stoke Therapeutics, Inc.

Mootness fee of $175,000 paid to resolve certain director compensation claims; company denies wrongdoing.
Proposed settlement filed Aug 20, 2024; includes corporate governance reforms and up to $415,000 in attorney fees.
Reforms cap director compensation at 65th percentile of peer group and require value-based equity grants and annual consultant review.
Court approval required; settlement hearing scheduled for Oct 28, 2024.
Company agrees to maintain reforms for five years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.